A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in Canada

Study Identifier
CMO-EPI-WH-0618
CT.gov Identifier
NCT04567589
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Study Details

Medical Condition
  • Uterine Fibroids
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    N/A
    Age
    N/A
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * HCPs have prescribed Fibristal for the indication of uterine fibroids within the past 6 months. * HCPs have provided permission to share their responses in aggregate to Health Canada.
    Exclusion Criteria:
    * HCPs who participated in the cognitive pre-testing of the survey questionnaire to be used for the study. * HCPs who have been direct employees of Allergan, ICON, Health Canada, or Professional Targeted Marketing (PTM) within the past 5 years.

    Protocol Summary

    This is a non-interventional, cross-sectional survey study to evaluate the effectiveness of the Additional Risk Minimization Measures for Fibristal among Healthcare Professionals (HCPs).

    Study Locations

    Location
    Status
    Location
    Clinical Trials Registry Team
    Irvine, California, United States, 92622
    Status
    Not applicable